Ufp Technologies (UFPT) AI Stock Analysis

• Market Cap: $1.94B
• Dividend Yield: N/A
• Average Volume (3M): 142.06K
• Price to Earnings (P/E): 29.1
• Beta (1Y): 1.47
• Revenue Growth: 29.47%
• EPS Growth: 23.24%
• Country: US
• Employees: 4,146
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.11
• Shares Outstanding: 7,712,444
• 10 Day Avg. Volume: 135,153
• 30 Day Avg. Volume: 142,059
• PEG Ratio: 1.04
• Price to Book (P/B): 5.47
• Price to Sales (P/S): 3.72
• P/FCF Ratio: 32.93
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 3.49
• Enterprise Value/Gross Profit: 12.22
• Enterprise Value/Ebitda: 18.60
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $278.00 ▲(13.98% Upside)

UFP Technologies' strong financial performance and strategic focus on high-margin opportunities in the medical device market are significant strengths. However, mixed technical indicators and operational challenges, particularly labor inefficiencies, present risks. The company's moderate valuation and future growth prospects in MedTech and robotic surgery are promising, but current challenges need to be addressed to fully realize potential.

Positive Factors

Free Cash Flow Strength

Sustained FCF growth indicates durable internal funding for capex, capacity expansion, acquisitions and debt paydown. Strong cash conversion reduces financing reliance, supports R&D and MedTech investment, and provides a cushion against cyclical order volatility over the next several quarters.

Healthy Profit Margins

Relatively robust gross and net margins reflect pricing power and manufacturing efficiency in engineered protective products. Margin durability supports reinvestment and earnings resilience, making growth in higher‑margin MedTech more accretive to long‑term profitability and cash generation.

MedTech Focus & Accretive M&A

Strategic pivot to high‑margin MedTech, immediate accretion from UNIPEC/TPI, and a nascent robotic surgery revenue stream provide structural growth drivers. Combined organic growth and targeted M&A improve product mix, customer stickiness and long‑term margin expansion prospects.

Negative Factors

Labor Inefficiency

Persistent labor inefficiencies materially compress margins and earnings power. If not resolved, higher operating costs and productivity shortfalls will reduce cash available for growth, complicate margin targets in MedTech, and may require restructuring or additional hiring/training investments.

Fulfillment & Turnover Risk

High turnover and order backlogs signal structural operational weaknesses that can delay revenue recognition, strain customer relationships, and raise working capital needs. Sustained fulfillment problems could impair growth traction in target verticals and increase costs to regain capacity.

Customer Concentration

Heavy reliance on a single large contract concentrates revenue and negotiating leverage with one customer. Loss, nonrenewal, or adverse repricing would materially impact revenues; scaling to meet expansion also requires capital and capacity, amplifying execution risk over the medium term.

Ufp Technologies Business Overview & Revenue Model

Company Description

UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging. The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets, which are applied in military uniform and gear components, automotive interior trim, athletic padding, environmentally protective packaging, air filtration, abrasive nail files, and protective cases and inserts. It markets and sells its products in the United States principally through a direct sales force, as well as independent manufacturer representatives. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

How the Company Makes Money

UFP Technologies generates revenue through the sale of its custom-engineered products, which are primarily focused on protective packaging, molded products, and specialty foam solutions. The company has multiple key revenue streams, including direct sales to customers in diverse sectors such as healthcare, automotive, and electronics. Additionally, UFP Technologies benefits from long-term contracts with major clients that ensure a steady flow of income. The company also invests in research and development to innovate and expand its product offerings, which helps maintain competitive advantage and drive sales growth. Strategic partnerships with suppliers and collaborations with clients for customized solutions further enhance its revenue potential, allowing UFP Technologies to capture a larger market share.

Ufp Technologies Financial Statement Overview

Summary

UFP Technologies exhibits a strong financial position with consistent revenue growth, solid profitability, and efficient cash flow management. The company's balance sheet is stable with moderate leverage, and its cash flow generation supports ongoing operations and growth initiatives. Overall, the financial statements reflect a well-managed company with a positive outlook in the medical devices industry.

Income Statement

Ufp Technologies has demonstrated strong revenue growth with a TTM revenue growth rate of 1.60%, indicating robust expansion. The company maintains healthy profitability with a gross profit margin of 28.76% and a net profit margin of 11.40% for the TTM. EBIT and EBITDA margins are also solid at 16.06% and 19.13%, respectively, reflecting efficient operations. Overall, the income statement shows a positive trajectory with consistent growth and profitability.

Balance Sheet

The balance sheet is stable with a debt-to-equity ratio of 0.42, indicating moderate leverage. The return on equity is strong at 18.93%, showcasing effective use of equity to generate profits. The equity ratio stands at 61.87%, reflecting a solid capital structure with a significant portion of assets financed by equity. While the company has increased its debt over time, it remains at manageable levels.

Cash Flow

Cash flow metrics are robust, with a free cash flow growth rate of 20.53% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.20, suggesting efficient conversion of income into cash. Additionally, the free cash flow to net income ratio of 0.87 highlights the company's ability to generate cash relative to its net income. Overall, cash flow performance is strong, supporting the company's growth and operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	597.95M	504.42M	400.07M	353.79M	206.32M	179.37M
Gross Profit	170.50M	146.69M	112.22M	90.26M	51.11M	44.68M
EBITDA	112.05M	95.80M	68.95M	67.37M	29.65M	24.63M
Net Income	67.12M	58.98M	44.92M	41.79M	15.89M	13.37M
Balance Sheet
Total Assets	652.82M	629.00M	404.14M	378.19M	334.13M	203.20M
Cash, Cash Equivalents and Short-Term Investments	18.23M	13.45M	5.26M	4.45M	11.12M	24.23M
Total Debt	165.51M	206.03M	46.04M	68.37M	84.36M	2.21M
Total Liabilities	248.91M	286.24M	118.05M	140.65M	139.69M	26.31M
Stockholders Equity	403.91M	342.76M	286.09M	237.54M	194.45M	176.89M
Cash Flow
Free Cash Flow	54.88M	56.94M	30.84M	3.96M	8.90M	20.67M
Operating Cash Flow	63.56M	66.59M	41.33M	17.74M	14.29M	25.04M
Investing Cash Flow	-12.35M	-210.16M	-10.49M	1.29M	-101.46M	-4.26M
Financing Cash Flow	-52.50M	152.39M	-30.02M	-25.89M	74.05M	-285.00K

Ufp Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 243.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Neutral. The current price of 243.9 is below the 20-day moving average (MA) of 251.48, above the 50-day MA of 234.23, and above the 200-day MA of 223.69, indicating a neutral trend. The MACD of 5.40 indicates Positive momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of 17.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UFPT.

Ufp Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	75 Outperform	$1.94B	29.11	18.31%	―	29.47%	23.24%
AHCO	74 Outperform	$1.36B	18.44	4.77%	―	-0.23%	―
CNMD	65 Neutral	$1.19B	24.71	6.60%	2.02%	4.69%	-51.57%
AORT	58 Neutral	$1.93B	-168.47	-2.45%	―	9.81%	-1067.00%
SIBN	57 Neutral	$719.43M	-32.44	-12.91%	―	23.27%	43.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	45 Neutral	$867.72M	-1.72	-38.71%	―	4.99%	-7151.40%

Ufp Technologies Corporate Events

UFP Technologies Highlights Strategic Focus in Investor Update

UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on high-margin, long-term manufacturing opportunities in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to strengthen customer relationships and expand its presence in various markets, including medical, aerospace, and defense. The announcement underscores UFP Technologies’ commitment to innovation and growth, with potential implications for stakeholders in terms of increased production capacity and market expansion.

The most recent analyst rating on (UFPT) stock is a Buy with a $252.00 price target. To see the full list of analyst forecasts on Ufp Technologies stock, see the UFPT Stock Forecast page.

UFP Technologies Announces CEO Retirement and Succession

On December 1, 2025, UFP Technologies announced the retirement of its long-serving CEO, R. Jeffrey Bailly, effective June 4, 2026. Bailly, who has led the company for 31 years, will transition to the role of Executive Chairman of the Board. Mitchell Rock, currently the President of UFP Technologies, will succeed Bailly as CEO. Rock has been with the company since 1991 and has held various leadership roles, demonstrating a deep understanding of the markets UFP serves. This leadership transition is expected to continue the company’s strategic growth and maintain its strong market position.

The most recent analyst rating on (UFPT) stock is a Buy with a $252.00 price target. To see the full list of analyst forecasts on Ufp Technologies stock, see the UFPT Stock Forecast page.